CStone Pharmaceuticals
Linlin Liu has extensive work experience in the pharmaceutical industry. Linlin started their career at WuXi AppTec in 2007, where they held various positions, including Senior Scientist and Group Leader. In 2012, they progressed to the role of Associate Director of Preclinical Project Management, where they were responsible for preclinical development and integrated IND-enabling project management. Linlin joined Shanghai Mab-venture Biopharmaceutical in 2016 as the Director of Nonclinical Development. Currently, Linlin Liu is working at CStone Pharmaceuticals as the Director of Preclinical Project Management and Project Leader.
Linlin Liu earned a Doctor of Philosophy (Ph.D.) in Pharmacology and Toxicology from the Shanghai Institute of Materia Medica between 2002 and 2007. They also have a PMP certification from the PMI-OC Project Management Institute Orange County Chapter, although the specific date of obtaining the certification is not provided.
This person is not in any teams
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.